Question from Deputy Barry Ward - PQ 22853-26
Deputy Ward asked about the provision of veoza (fezolinetant) under the drug payment scheme. Read the HSE response.
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy Ward asked about the provision of veoza (fezolinetant) under the drug payment scheme. Read the HSE response.
Deputy Devine asked the HSE to recognise the time-critical nature of Friedrich's Ataxia during the price negotiations with the drug manufacturer.
Deputy Ward asked about the use of veoza (fezolinetant) in the treatment of cancer patients. Read the HSE response.
Deputy Tóibín asked about instances where IT personnel were deployed within CHI hospitals without appropriate Garda vetting. Read the HSE response.
Deputy Sherlock asked for an update on the recruitment of a clinical lead to support the implementation of the National Model of Care for Epilepsy.
Deputy Tóibín asked about formal training in place for senior IT personnel to operate safely and effectively within intensive care units. Read the HSE response.
Deputy Tóibín asked about the Chief Information Officer (CIO) of Children’s Health Ireland. Read the HSE response.
Deputy Tóibín asked about the reported availability of multiple IT staff witnesses. Read the HSE response.
Deputy Tóibín asked that appropriate training and clear protocols are in place for IT personnel required to enter live surgical settings. Read the response.
Deputy Tóibín asked whether any external review or escalation to HIQA has been made in relation to NIMIS failures. Read the HSE response.